These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 18534623

  • 1. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
    Eser D, Leicht G, Baghai T, Pogarell O, Schüle C, Karch S, Nothdurfter C, Rupprecht R, Mulert C.
    J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
    [Abstract] [Full Text] [Related]

  • 2. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
    Koszycki D, Zacharko RM, Le Mellédo JM, Bradwejn J.
    Depress Anxiety; 1998 Jan; 8(1):1-7. PubMed ID: 9750972
    [Abstract] [Full Text] [Related]

  • 3. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P, Eser D, Aicher S, Schüle C, Baghai TC, Padberg F, Ella R, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
    [Abstract] [Full Text] [Related]

  • 4. Effects of propranolol on symptom and endocrine responses to pentagastrin.
    Khan S, Liberzon I, Abelson JL.
    Psychoneuroendocrinology; 2004 Oct; 29(9):1163-71. PubMed ID: 15219640
    [Abstract] [Full Text] [Related]

  • 5. HPA axis activity in patients with panic disorder: review and synthesis of four studies.
    Abelson JL, Khan S, Liberzon I, Young EA.
    Depress Anxiety; 2007 Oct; 24(1):66-76. PubMed ID: 16845643
    [Abstract] [Full Text] [Related]

  • 6. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K.
    Depress Anxiety; 2006 Oct; 23(3):139-44. PubMed ID: 16470820
    [Abstract] [Full Text] [Related]

  • 7. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects.
    Abelson JL, Liberzon I, Young EA, Khan S.
    Arch Gen Psychiatry; 2005 Jun; 62(6):668-75. PubMed ID: 15939844
    [Abstract] [Full Text] [Related]

  • 8. CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers.
    van Duinen MA, Schruers KR, Maes M, Griez EJ.
    J Psychopharmacol; 2005 May; 19(3):243-7. PubMed ID: 15888509
    [Abstract] [Full Text] [Related]

  • 9. Loudness dependence of evoked dipole source activity during acute serotonin challenge in females.
    Norra C, Becker S, Bröcheler A, Kawohl W, Kunert HJ, Buchner H.
    Hum Psychopharmacol; 2008 Jan; 23(1):31-42. PubMed ID: 17868194
    [Abstract] [Full Text] [Related]

  • 10. Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone.
    Demiralay C, Jahn H, Kellner M, Yassouridis A, Wiedemann K.
    World J Biol Psychiatry; 2012 Oct; 13(7):526-34. PubMed ID: 22111662
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
    Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la Motte S, Engel R, Kucher K, Rupprecht R.
    Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
    [Abstract] [Full Text] [Related]

  • 12. No association between chronic cannabis use and loudness dependence of auditory evoked potentials as indicator of central serotonergic neurotransmission.
    Roser P, Della B, Norra C, Juckel G, Uhl I.
    Neurosci Lett; 2009 Nov 13; 465(2):113-7. PubMed ID: 19766579
    [Abstract] [Full Text] [Related]

  • 13. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A, Holsboer F, Rupprecht R.
    Neuropsychopharmacology; 2000 Mar 13; 22(3):251-6. PubMed ID: 10693152
    [Abstract] [Full Text] [Related]

  • 14. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
    Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schüle C, Rupprecht R, Romeo E.
    Neuropsychopharmacology; 2005 Jan 13; 30(1):192-5. PubMed ID: 15467707
    [Abstract] [Full Text] [Related]

  • 15. The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings.
    O'Neill BV, Croft RJ, Nathan PJ.
    Hum Psychopharmacol; 2008 Jul 13; 23(5):355-70. PubMed ID: 18421800
    [Abstract] [Full Text] [Related]

  • 16. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C, Agorastos A, Yassouridis A, Jahn H, Wiedemann K, Kellner M.
    Psychoneuroendocrinology; 2017 Feb 13; 76():14-18. PubMed ID: 27871026
    [Abstract] [Full Text] [Related]

  • 17. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazières A, Luthringer R.
    J Psychopharmacol; 2011 Jan 13; 25(1):52-9. PubMed ID: 20498136
    [Abstract] [Full Text] [Related]

  • 18. Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder.
    Masdrakis VG, Markianos M, Oulis P.
    Psychiatry Res; 2015 Sep 30; 229(1-2):75-81. PubMed ID: 26243374
    [Abstract] [Full Text] [Related]

  • 19. The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls.
    Park YM, Lee SH, Kim S, Bae SM.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar 17; 34(2):313-6. PubMed ID: 20005279
    [Abstract] [Full Text] [Related]

  • 20. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
    Katzman MA, Koszycki D, Bradwejn J.
    Depress Anxiety; 2004 Mar 17; 20(2):51-8. PubMed ID: 15390214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.